chevron_leftBack
As of 5 June 2026, Genovate Biotechnology Co., Ltd. has a market cap of $99.22M USD, ranking #25628 globally and #1391 in Taiwan.
It ranks #2299 in the Healthcare sector, and #834 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$99.22MUSD
3.12B TWD
Enterprise Value
$84.0MUSD
2.64B TWD
Revenue (TTM)
$15.65MUSD
492.41M TWD
EBITDA (TTM)
$1.34MUSD
42.03M TWD
Net Income (TTM)
$371.2KUSD
11.68M TWD
EBITDA Margin
8.5%
Profit Margin
2.4%
PE Ratio
274.5
PS Ratio
6.3
PB Ratio
2.3
EV/EBITDA
64.7
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Chia-Chen Chu
open_in_new
Employees
190
Founded
1982
Website
genovate-bio.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -1.3% | -8.5% | -14% | -8.5% | 43% | 36% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
4130
健亞生物科技股份有限公司
ISIN: TW0004130000
Shares Out.:
Shares Outstanding:
117.426M1
Shares Float:
72.933M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
27.45 TWD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Genovate Biotechnology Co., Ltd.
Genovate Biotechnology Co., Ltd. engages in the research, development, manufacture, production, and sale of products to prevent and treat diseases caused by viruses and bacteria in Taiwan. It provides drugs, APIs, intermediates, and release agents for the treatment of cardiovascular, esophageal, gastrointestinal, cancer, and autoimmune diseases; and controlled-release dosage forms of Western medicine, as well as cosmetics. Genovate Biotechnology Co., Ltd. was founded in 1982 and is based in Hsinchu City, Taiwan.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
TWSE: 6446
|
$7.8B
8K%
245.34B TWD
|
48.6
|
|
TWSE: 1795
|
$1.84B
2K%
57.95B TWD
|
12.2
|
|
TPEX: 4123
|
$925.15M
832%
29.11B TWD
|
3.4
|
|
TPEX: 6535
|
$808.94M
715%
25.46B TWD
|
-
|
|
TPEX: 4743
|
$788.78M
695%
24.82B TWD
|
-
|
|
TPEX: 4105
|
$583.89M
488%
18.38B TWD
|
11.8
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
768K%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
551K%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
363K%
|
97.4
|
|
SIX: RO
|
$323.4B
326K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$289.25B
291K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$276.26B
278K%
218.9B CHF
|
20.5
|
chevron_leftBack